Author + information
- J. Brent Muhlesteina,b,
- Heidi Maya,b,
- Oxana Galenkoa,b,
- Kirk Knowltona,b,
- James Otvosa,b,
- Margery Connellya,b,
- Donald Lappea,b and
- Jeffrey Andersona,b
Background: GlycA, a novel marker of inflammation, has been associated with future CV risk among patients with or without pre-existing coronary artery disease (CAD). Whether GlycA is an independent and additive predictor of high sensitivity C-reactive protein (HS-CRP) needs further study.
Methods: Plasma GlycA and HS-CRP concentrations were determined in 2,996 pts who underwent angiography for CAD determination and were enrolled in the Intermountain Heart Collaborative Study. Baseline GlycA and HS-CRP concentrations were stratified into high (H) and low (L) categories by their median values. Multivariable Cox hazard regression analyses were utilized to determine the association between GlycA and HS-CRP and major adverse CV events (MACE).
Results: Pts (64±12 yrs, 66% male, 26% diabetes, 42% ACS presentation, 65% CAD) were followed for 7.0±2.8 yrs. GlycA and HS-CRP were moderately correlated (Spearman r=0.463, p<0.0001). Combined MACE event rates were 33.5%, 41.3%, 35.7% and 49.1% for L/L, L/H, H/L and H/H categories of GlycA/HS-CRP, respectively (p-trend <0.0001). Multivariable hazard ratios for MACE components are shown in the Figure. The interaction between GlycA and HS-CRP was statistically significant for the outcome of death (p=0.03).
Conclusions: Baseline levels of both GlycA and HS-CRP were found to be independent and additive markers of risk for future MACE, especially death and HF admission. Further studies are needed to determine the differential pathophysiology of these two markers.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Interventional Cardiology: Translation and Pre-Clinical Research
Abstract Category: 25. Interventional Cardiology: Translation and Pre-clinical Research
Presentation Number: 1116-190
- 2017 American College of Cardiology Foundation